Bausch Health Announces Second Quarter 2025 Results
1. Q2 2025 revenues rose 5%, reaching $2.53 billion. 2. GAAP net income increased to $148 million from $10 million last year. 3. Adjusted EBITDA grew 6% to $842 million, marking nine consecutive growth quarters. 4. Bausch Health plans a $900 million debt repayment post-quarter. 5. Upcoming acquisition of DURECT Corporation aims to enhance hepatology focus.